International Clinical and Medical Case Reports Journal
Case Report Article (ISSN: 2832-5788)

Prolactinoma

Praneeth Ulavala[1*], Harichandana Kalangi[2] and Sravanthi Narapaneni[1]

[1]Narayana Medical College and Hospitals, Nellore, Andhra Pradesh, 524003, India

[2]Kamineni Academy of Medical Sciences and Research, L. B. Nagar, Hyderabad, Telangana, 500068, India

Citation: *Ulavala P, Kalangi H, Narapaneni S. Prolactinoma. Int Clinc Med Case Rep Jour. 2024;3(10):1-5.*

Received Date: 20 September, 2024**; Accepted Date:** 01 October, 2024**; Published Date:** 04 October, 2024

[*]**Corresponding author:** Praneeth Ulavala. Narayana Medical College and Hospitals, Nellore, Andhra Pradesh, 524003, India

ABSTRACT

Prolactinomas are benign pituitary tumors characterized by excessive secretion of prolactin. While more common in females, these tumors can also significantly impact male patients, leading to symptoms such as hypogonadism, infertility and gynecomastia. Traditional treatments include dopamine agonists, surgery and in some cases, radiation therapy with varying degrees of success. This article explores the clinical presentation, diagnostic challenges and therapeutic approaches specific to prolactinomas in male patients.

Prolactinomas account for approximately 40% of pituitary adenomas, with their impact on male patients often being underrecognized due to atypical presentations compared to females. These tumors can result in reduced testosterone levels, sexual dysfunction and even osteoporosis due to chronic hypogonadism. The primary treatment modality, dopamine agonists, aims to normalize prolactin levels, shrink tumor size and restore gonadal function. However, resistance to dopamine agonists and side effects remain challenges in management. In such cases, surgical intervention or radiation therapy may be considered.

In conclusion, managing prolactinomas in male patients requires a nuanced approach, considering the distinct clinical presentations and challenges associated with treatment. Early diagnosis and appropriate therapy are critical for preserving quality of life and preventing long-term complications.

Keywords: Prolactinoma; Male hypogonadism; Dopamine agonists; Pituitary adenoma; Prolactin management

INTRODUCTION

Prolactinomas, the most common type of pituitary adenomas are benign tumors of the anterior pituitary gland that result in excessive production of prolactin. While they are more frequently diagnosed in women, prolactinomas in men present a unique set of challenges, often manifesting with symptoms that lead to delayed diagnosis and treatment. Prolactin, a hormone primarily associated with lactation in females, plays various roles in males, including influencing reproductive function by regulating testosterone levels.

In male patients, prolactinomas often present with symptoms related to hypogonadism, such as decreased libido, erectile dysfunction and infertility. In some cases, gynecomastia and galactorrhea may also occur. The delay in diagnosis is often due to the subtlety of these symptoms and the lower index of suspicion for prolactinomas in men. This article provides an in-depth review of prolactinoma in male patients, focusing on its clinical presentation, diagnostic workup and management strategies, including the use of dopamine agonists, surgical intervention and radiation therapy.

LITERATURE SURVEY

Several studies have examined the clinical characteristics and treatment outcomes of prolactinomas in men. Research indicates that prolactinomas are less frequently diagnosed in men, partly due to the less apparent symptoms and later onset of clinical signs compared to women. The most common presenting symptoms in men include sexual dysfunction and symptoms related to hypogonadism.

Dopamine agonists, such as cabergoline and bromocriptine are the first-line treatment for prolactinomas. These medications effectively lower prolactin levels and reduce tumor size in most patients. However, studies have highlighted that some patients exhibit resistance to these drugs, necessitating alternative treatment approaches, including surgery or radiotherapy.

Long-term studies have shown that while dopamine agonists are generally effective, the recurrence of hyperprolactinemia after discontinuation of therapy remains a concern. Additionally, surgical outcomes are influenced by tumor size and invasiveness with transsphenoidal surgery being the preferred approach for tumors that are resistant to medical therapy or cause significant mass effect.

CASE PRESENTATION

A 35year-old male presented to the clinic with complaints of significant weight gain, decreased libido and persistent lethargy over the past 2 months. The patient noted that these symptoms particularly emerged after recovering from COVID-19. He denied experiencing any headaches, visual disturbances or erectile dysfunction. He also reported neglecting self-care and struggling with low self-esteem. The patient's mother had a history of thyroid problems, but there was no other significant family history.

Physical Examination:

Testicular size and consistency: Normal
Body and facial hair pattern: Normal
Gynecomastia: Absent
Nipple sensitivity: Absent
Visual acuity and visual fields: Normal
Cranial nerve examination: Normal

Investigations:

Given the patient's history, further evaluation was conducted, including routine laboratory tests and prolactin levels. Prolactin levels were found to be 150 ng/ml (around 10 times greater than normal), indicating a possible prolactinoma. An MRI was performed, which revealed a 11 x 12 x 9 mm mass in the left pituitary gland. There is remodeling of the sellar floor, which slopes to the left. There is displacement of the infundibulum and normal pituitary tissue to the right. There is slight tilting of the chiasm, but without chiasmal contact.

Diagnosis and Treatment:

The patient was diagnosed with prolactinoma and was started on Cabergoline 0.25 mg. Following treatment, he showed significant improvement, including a weight loss of approximately 120 pounds. He continues to follow up regularly every six months and has maintained good health since the initiation of treatment.

DISCUSSION

The management of prolactinomas in male patients presents unique challenges due to the differences in clinical presentation compared to female patients.

Men are more likely to present with larger tumors at the time of diagnosis, leading to more pronounced symptoms related to mass effect, such as headaches and visual disturbances, alongside the hormonal symptoms of hypogonadism.

Clinical Presentation:

In men, prolactinomas often lead to symptoms associated with decreased testosterone production. These include reduced libido, erectile dysfunction and infertility. Gynecomastia and less commonly, galactorrhea may also be observed. Because these symptoms can be attributed to a range of other conditions, the diagnosis of prolactinoma is frequently delayed.

Diagnostic Workup:

The diagnosis of a prolactinoma in men involves measuring serum prolactin levels and performing imaging studies, typically magnetic resonance imaging (MRI) of the pituitary gland, to assess tumor size and location. Elevated prolactin levels, often significantly higher than normal are indicative of a prolactinoma. The MRI provides critical information about the tumor's size and any possible extension into surrounding structures, such as the optic chiasm, which can lead to visual field deficits.

Treatment Strategies:

The cornerstone of prolactinoma treatment in men is medical therapy with dopamine agonists. These medications, particularly cabergoline, have been shown to normalize prolactin levels, shrink tumor size and improve symptoms of hypogonadism in the majority of patients. Cabergoline is preferred due to its higher efficacy and lower side effect profile compared to bromocriptine.

However, resistance to dopamine agonists is a significant challenge, occurring in approximately 10-20% of patients. In such cases or when tumors cause significant neurological symptoms, surgical intervention may be necessary. Transsphenoidal surgery, a minimally invasive procedure, is the preferred surgical approach, offering good outcomes with relatively low morbidity. Radiation therapy is typically reserved for cases where both medical and surgical treatments fail or in patients with recurrent tumors.

Side Effects and Complications:

Dopamine agonists are generally well-tolerated, but they can cause side effects such as nausea, dizziness and in rare cases, impulse control disorders. Surgical complications are rare but can include cerebrospinal fluid leaks, diabetes insipidus and in rare cases, damage to the surrounding pituitary tissue.

Long-term Management:

Long-term follow-up is essential for patients with prolactinomas, given the potential for recurrence of hyperprolactinemia, particularly after discontinuation of dopamine agonists. Regular monitoring of prolactin levels and periodic imaging are recommended to assess for tumor regrowth. In cases of recurrence, re-initiation of medical therapy or additional surgery may be necessary.

CONCLUSION

In conclusion, prolactinomas in male patients require a tailored approach to diagnosis and management. The clinical presentation, often marked by symptoms of hypogonadism, necessitates a high index of suspicion for timely diagnosis. Dopamine agonists remain the first-line treatment, offering effective control of prolactin levels and tumor size in most patients. However, resistance to these medications and the potential for recurrence post-treatment highlight the need for ongoing research into alternative therapies and long-term management strategies.

Surgical intervention, primarily via the transsphenoidal approach, provides a viable option for patients with large tumors or those resistant to medical therapy. Radiation therapy, while less commonly employed, remains a critical tool for managing recurrent or refractory cases.

Ultimately, the management of prolactinomas in male patients should be individualized, taking into account the specific clinical scenario, tumor characteristics and patient preferences. With appropriate treatment, most patients can achieve significant symptom relief and improved quality of life.

Future scope:

The future of prolactinoma management in male patients lies in the continued refinement of treatment modalities, particularly in the realm of medical therapy. Research is ongoing into new dopamine agonists with improved efficacy and reduced side effects, as well as novel therapeutic approaches targeting the molecular pathways involved in prolactinoma development.

Advancements in surgical techniques and imaging technology also promise to enhance the precision and outcomes of surgical interventions. Additionally, the exploration of genetic and molecular markers may offer new insights into individualized treatment strategies, potentially leading to earlier diagnosis and more effective, targeted therapies.

As our understanding of prolactinomas continues to evolve, the goal remains to provide male patients with prolactinomas a future where their condition is managed effectively, with minimal impact on their quality of life. The ongoing development of more sophisticated and patient-centered treatment strategies offers hope for achieving this objective.